Who is eligible for clinical trial NCT02264678?

Participants must meet protocol criteria for Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT02264678 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-23

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents (NCT02264678)

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced malignancies. The study design allows an investigation of optimal combination dose of ceralasertib with other anti-cancer treatments, with intensive safety monitoring to ensure the safety of the patients. The initial combination to be investigated is ceralasertib with carboplatin. The second combination to be investigated is ceralasertib with Olaparib. The third combination to be investigated is ceralasertib with durvalumab. The fourth module will investigate the effect of food on ceralasertib absorption and the effect of ceralasertib on ECG parameter. The fifth module to be investigated is ceralasertib with AZD5305.

Who can join: Review the eligibility criteria below.

Location: Research Site — Duarte, California

Age range: 18 Years to 130 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (28 Sites)

Showing the first 25 of 28 sites.

Research Site — Duarte, California
Research Site — Irvine, California
Research Site — Los Angeles, California
Research Site — Los Angeles, California
Research Site — Newport Beach, California
Research Site — Boston, Massachusetts
Research Site — New York, New York
Research Site — Philadelphia, Pennsylvania
Research Site — Bordeaux,
Research Site — Lyon,
Research Site — Saint-Herblain,
Research Site — Villejuif,
Research Site — Goyang-si,
Research Site — Seongnam-si,
Research Site — Seoul,
Research Site — Seoul,
Research Site — Seoul,
Research Site — Bristol,
Research Site — Cambridge,
Research Site — Coventry,
Research Site — London,
Research Site — London,
Research Site — London,
Research Site — London,
Research Site — Manchester,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗